Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study
Hyeontaek Hwang, Jung-Kyu Lee, Sun Mi Choi, Yeon Joo Lee, Young-Jae Cho, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee, Young Whan Kim, Jong Sun Park
Korean J Intern Med. 2022;37(2):366-376. Published online 2021 Jul 27 DOI: https://doi.org/10.3904/kjim.2020.559
Citations to this article as recorded by 
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study
Ruiming Zhao, Bingbing Xie, Xin Wang, Xinran Zhang, Yanhong Ren, Chen Wang, Huaping Dai
Pulmonary Pharmacology & Therapeutics.2024; 84: 102287. CrossRef
Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal, Jin Woo Song
Frontiers in Pharmacology.2023;[Epub] CrossRef
Nailfold capillaroscopy findings of interstitial pneumonia with autoimmune features
Sang-Heon Lee, Hong Ki Min, Se-Hee Kim, Young Whan Kim, Kwang Ha Yoo, Hee Joung Kim, In Ae Kim, Hae-Rim Kim
The Korean Journal of Internal Medicine.2023; 38(6): 903. CrossRef
Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
Ho Young Lee, So Young Jung, Ji Hoon Jang, Junghae Ko, Dae-Wook Kim, Minyoung Her, Jae Ha Lee
Life.2023; 13(11): 2118. CrossRef